An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma Article Swipe
Kevin B. Givechian
,
Chad Garner
,
Stephen C. Benz
,
Bing Song
,
Shahrooz Rabizadeh
,
Patrick Soon‐Shiong
·
YOU?
·
· 2019
· Open Access
·
· DOI: https://doi.org/10.18632/oncotarget.26748
YOU?
·
· 2019
· Open Access
·
· DOI: https://doi.org/10.18632/oncotarget.26748
The tumor microenvironment consists of an intricately organized system through which immune cells and cancer cells may communicate to regulate anti-tumor immunogenicity. To this end, non-small cell lung cancer (NSCLC) has been shown to activate a variety of immunological mechanisms, thereby broadening our understanding of lung cancer immunobiology. However, while recent work has highlighted the importance of NSCLC immunology and prognosis, studies have not yet examined the tumor microenvironment (TME) globally in regards to the survival outcomes between two major NSCLC subtypes: lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). In the present study, we identify an immunogenic tumor microenvironment state in NSCLC that is enriched for the lung adenocarcinoma subtype. By utilizing TME cell enrichment scores and RNA-seq expression data, we show that the inflamed TME is associated with favorable patient survival in lung adenocarcinoma, but this does not hold true for lung squamous cell carcinoma. Moreover, differentially regulated pathways between immune-inflamed and immune-excluded tumors within LUAD and LUSC were not subtype specific. Instead, immune-inflamed LUSC samples possessed elevated immune checkpoint marker expression when compared to those of the LUAD samples, thereby offering a putative explanation for our prognostic observations. These results shed light on the immunological prognostic effects within lung cancer and may encourage further TME exploration between these two subtypes as the landscape of NSCLC therapy progresses.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.18632/oncotarget.26748
- https://www.oncotarget.com/article/26748/pdf/
- OA Status
- diamond
- Cited By
- 25
- References
- 64
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2919023968
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2919023968Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.18632/oncotarget.26748Digital Object Identifier
- Title
-
An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinomaWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2019Year of publication
- Publication date
-
2019-03-05Full publication date if available
- Authors
-
Kevin B. Givechian, Chad Garner, Stephen C. Benz, Bing Song, Shahrooz Rabizadeh, Patrick Soon‐ShiongList of authors in order
- Landing page
-
https://doi.org/10.18632/oncotarget.26748Publisher landing page
- PDF URL
-
https://www.oncotarget.com/article/26748/pdf/Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://www.oncotarget.com/article/26748/pdf/Direct OA link when available
- Concepts
-
Tumor microenvironment, Adenocarcinoma, Lung cancer, Medicine, Cancer research, Lung, Cancer, Immunology, Oncology, Immune system, Internal medicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
25Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 3, 2024: 1, 2023: 5, 2022: 3, 2021: 6Per-year citation counts (last 5 years)
- References (count)
-
64Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2919023968 |
|---|---|
| doi | https://doi.org/10.18632/oncotarget.26748 |
| ids.doi | https://doi.org/10.18632/oncotarget.26748 |
| ids.mag | 2919023968 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/30956762 |
| ids.openalex | https://openalex.org/W2919023968 |
| fwci | 2.00883892 |
| type | article |
| title | An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma |
| biblio.issue | 19 |
| biblio.volume | 10 |
| biblio.last_page | 1849 |
| biblio.first_page | 1840 |
| topics[0].id | https://openalex.org/T10158 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998000264167786 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Immunotherapy and Biomarkers |
| topics[1].id | https://openalex.org/T10417 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9995999932289124 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2740 |
| topics[1].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[1].display_name | Lung Cancer Treatments and Mutations |
| topics[2].id | https://openalex.org/T10580 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.9991000294685364 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2403 |
| topics[2].subfield.display_name | Immunology |
| topics[2].display_name | Immunotherapy and Immune Responses |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2776107976 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8125475645065308 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1786433 |
| concepts[0].display_name | Tumor microenvironment |
| concepts[1].id | https://openalex.org/C2781182431 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7613834142684937 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q356033 |
| concepts[1].display_name | Adenocarcinoma |
| concepts[2].id | https://openalex.org/C2776256026 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7233058214187622 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q47912 |
| concepts[2].display_name | Lung cancer |
| concepts[3].id | https://openalex.org/C71924100 |
| concepts[3].level | 0 |
| concepts[3].score | 0.5642356276512146 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[3].display_name | Medicine |
| concepts[4].id | https://openalex.org/C502942594 |
| concepts[4].level | 1 |
| concepts[4].score | 0.526185154914856 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[4].display_name | Cancer research |
| concepts[5].id | https://openalex.org/C2777714996 |
| concepts[5].level | 2 |
| concepts[5].score | 0.4936167001724243 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q7886 |
| concepts[5].display_name | Lung |
| concepts[6].id | https://openalex.org/C121608353 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4298224449157715 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[6].display_name | Cancer |
| concepts[7].id | https://openalex.org/C203014093 |
| concepts[7].level | 1 |
| concepts[7].score | 0.380879282951355 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[7].display_name | Immunology |
| concepts[8].id | https://openalex.org/C143998085 |
| concepts[8].level | 1 |
| concepts[8].score | 0.37482893466949463 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[8].display_name | Oncology |
| concepts[9].id | https://openalex.org/C8891405 |
| concepts[9].level | 2 |
| concepts[9].score | 0.3663473129272461 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[9].display_name | Immune system |
| concepts[10].id | https://openalex.org/C126322002 |
| concepts[10].level | 1 |
| concepts[10].score | 0.3154916763305664 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[10].display_name | Internal medicine |
| keywords[0].id | https://openalex.org/keywords/tumor-microenvironment |
| keywords[0].score | 0.8125475645065308 |
| keywords[0].display_name | Tumor microenvironment |
| keywords[1].id | https://openalex.org/keywords/adenocarcinoma |
| keywords[1].score | 0.7613834142684937 |
| keywords[1].display_name | Adenocarcinoma |
| keywords[2].id | https://openalex.org/keywords/lung-cancer |
| keywords[2].score | 0.7233058214187622 |
| keywords[2].display_name | Lung cancer |
| keywords[3].id | https://openalex.org/keywords/medicine |
| keywords[3].score | 0.5642356276512146 |
| keywords[3].display_name | Medicine |
| keywords[4].id | https://openalex.org/keywords/cancer-research |
| keywords[4].score | 0.526185154914856 |
| keywords[4].display_name | Cancer research |
| keywords[5].id | https://openalex.org/keywords/lung |
| keywords[5].score | 0.4936167001724243 |
| keywords[5].display_name | Lung |
| keywords[6].id | https://openalex.org/keywords/cancer |
| keywords[6].score | 0.4298224449157715 |
| keywords[6].display_name | Cancer |
| keywords[7].id | https://openalex.org/keywords/immunology |
| keywords[7].score | 0.380879282951355 |
| keywords[7].display_name | Immunology |
| keywords[8].id | https://openalex.org/keywords/oncology |
| keywords[8].score | 0.37482893466949463 |
| keywords[8].display_name | Oncology |
| keywords[9].id | https://openalex.org/keywords/immune-system |
| keywords[9].score | 0.3663473129272461 |
| keywords[9].display_name | Immune system |
| keywords[10].id | https://openalex.org/keywords/internal-medicine |
| keywords[10].score | 0.3154916763305664 |
| keywords[10].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.18632/oncotarget.26748 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S126644158 |
| locations[0].source.issn | 1949-2553 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1949-2553 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Oncotarget |
| locations[0].source.host_organization | https://openalex.org/P4310316297 |
| locations[0].source.host_organization_name | Impact Journals LLC |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310316297 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.oncotarget.com/article/26748/pdf/ |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Oncotarget |
| locations[0].landing_page_url | https://doi.org/10.18632/oncotarget.26748 |
| locations[1].id | pmid:30956762 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Oncotarget |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/30956762 |
| locations[2].id | pmh:oai:europepmc.org:5435254 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400806 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Europe PMC (PubMed Central) |
| locations[2].source.host_organization | https://openalex.org/I1303153112 |
| locations[2].source.host_organization_name | European Bioinformatics Institute |
| locations[2].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[2].license | cc-by |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/cc-by |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/6442995 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5015535736 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-8155-2058 |
| authorships[0].author.display_name | Kevin B. Givechian |
| authorships[0].affiliations[0].raw_affiliation_string | NantOmics LLC, Culver City, CA 90232, USA |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Kevin B. Givechian |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | NantOmics LLC, Culver City, CA 90232, USA |
| authorships[1].author.id | https://openalex.org/A5109320534 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Chad Garner |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210107048 |
| authorships[1].affiliations[0].raw_affiliation_string | NantHealth, Inc. NantWorks, Culver City, CA 90232, USA |
| authorships[1].institutions[0].id | https://openalex.org/I4210107048 |
| authorships[1].institutions[0].ror | https://ror.org/0121y9f76 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210107048 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | NantWorks (United States) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Chad Garner |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | NantHealth, Inc. NantWorks, Culver City, CA 90232, USA |
| authorships[2].author.id | https://openalex.org/A5007814512 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-4067-0602 |
| authorships[2].author.display_name | Stephen C. Benz |
| authorships[2].affiliations[0].raw_affiliation_string | NantOmics LLC, Culver City, CA 90232, USA |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Steve Benz |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | NantOmics LLC, Culver City, CA 90232, USA |
| authorships[3].author.id | https://openalex.org/A5038012475 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-9356-2333 |
| authorships[3].author.display_name | Bing Song |
| authorships[3].affiliations[0].raw_affiliation_string | NantOmics LLC, Culver City, CA 90232, USA |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Bing Song |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | NantOmics LLC, Culver City, CA 90232, USA |
| authorships[4].author.id | https://openalex.org/A5052356018 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-8609-7645 |
| authorships[4].author.display_name | Shahrooz Rabizadeh |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210107048 |
| authorships[4].affiliations[0].raw_affiliation_string | NantHealth, Inc. NantWorks, Culver City, CA 90232, USA; NantOmics LLC, Culver City, CA 90232, USA |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I4210107048 |
| authorships[4].affiliations[1].raw_affiliation_string | NantHealth, Inc. NantWorks, Culver City, CA 90232, USA |
| authorships[4].institutions[0].id | https://openalex.org/I4210107048 |
| authorships[4].institutions[0].ror | https://ror.org/0121y9f76 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210107048 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | NantWorks (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Shahrooz Rabizadeh |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | NantHealth, Inc. NantWorks, Culver City, CA 90232, USA, NantHealth, Inc. NantWorks, Culver City, CA 90232, USA; NantOmics LLC, Culver City, CA 90232, USA |
| authorships[5].author.id | https://openalex.org/A5087962211 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-4682-8298 |
| authorships[5].author.display_name | Patrick Soon‐Shiong |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210107048 |
| authorships[5].affiliations[0].raw_affiliation_string | NantHealth, Inc. NantWorks, Culver City, CA 90232, USA; NantOmics LLC, Culver City, CA 90232, USA |
| authorships[5].affiliations[1].institution_ids | https://openalex.org/I4210107048 |
| authorships[5].affiliations[1].raw_affiliation_string | NantHealth, Inc. NantWorks, Culver City, CA 90232, USA |
| authorships[5].affiliations[2].institution_ids | https://openalex.org/I4210107048 |
| authorships[5].affiliations[2].raw_affiliation_string | NantBioscience, Inc. NantWorks, Culver City, CA 90232, USA |
| authorships[5].institutions[0].id | https://openalex.org/I4210107048 |
| authorships[5].institutions[0].ror | https://ror.org/0121y9f76 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210107048 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | NantWorks (United States) |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Patrick Soon-Shiong |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | NantBioscience, Inc. NantWorks, Culver City, CA 90232, USA, NantHealth, Inc. NantWorks, Culver City, CA 90232, USA, NantHealth, Inc. NantWorks, Culver City, CA 90232, USA; NantOmics LLC, Culver City, CA 90232, USA |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.oncotarget.com/article/26748/pdf/ |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10158 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998000264167786 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Immunotherapy and Biomarkers |
| related_works | https://openalex.org/W4307869277, https://openalex.org/W2981696006, https://openalex.org/W2064573700, https://openalex.org/W2554284703, https://openalex.org/W4211132779, https://openalex.org/W2955300884, https://openalex.org/W1972945471, https://openalex.org/W2388915439, https://openalex.org/W1978595424, https://openalex.org/W2066500467 |
| cited_by_count | 25 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 3 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 1 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 5 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 3 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 6 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 6 |
| counts_by_year[6].year | 2019 |
| counts_by_year[6].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | doi:10.18632/oncotarget.26748 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S126644158 |
| best_oa_location.source.issn | 1949-2553 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1949-2553 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Oncotarget |
| best_oa_location.source.host_organization | https://openalex.org/P4310316297 |
| best_oa_location.source.host_organization_name | Impact Journals LLC |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310316297 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.oncotarget.com/article/26748/pdf/ |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Oncotarget |
| best_oa_location.landing_page_url | https://doi.org/10.18632/oncotarget.26748 |
| primary_location.id | doi:10.18632/oncotarget.26748 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S126644158 |
| primary_location.source.issn | 1949-2553 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1949-2553 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Oncotarget |
| primary_location.source.host_organization | https://openalex.org/P4310316297 |
| primary_location.source.host_organization_name | Impact Journals LLC |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310316297 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.oncotarget.com/article/26748/pdf/ |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Oncotarget |
| primary_location.landing_page_url | https://doi.org/10.18632/oncotarget.26748 |
| publication_date | 2019-03-05 |
| publication_year | 2019 |
| referenced_works | https://openalex.org/W2106787323, https://openalex.org/W2525493424, https://openalex.org/W2801309958, https://openalex.org/W2744743363, https://openalex.org/W2096064375, https://openalex.org/W2150633526, https://openalex.org/W1827997917, https://openalex.org/W143964993, https://openalex.org/W2890156321, https://openalex.org/W2155755553, https://openalex.org/W2008387441, https://openalex.org/W2071793654, https://openalex.org/W2189583961, https://openalex.org/W2554666790, https://openalex.org/W2619870611, https://openalex.org/W2894382482, https://openalex.org/W2952001873, https://openalex.org/W2098683355, https://openalex.org/W2028433016, https://openalex.org/W2776402318, https://openalex.org/W2089220120, https://openalex.org/W2953072960, https://openalex.org/W2769896725, https://openalex.org/W4244844690, https://openalex.org/W2796865811, https://openalex.org/W2302719382, https://openalex.org/W2796183066, https://openalex.org/W2027516399, https://openalex.org/W2796207838, https://openalex.org/W2737046088, https://openalex.org/W2137596844, https://openalex.org/W2113570557, https://openalex.org/W2089716875, https://openalex.org/W2339631364, https://openalex.org/W2735284102, https://openalex.org/W2766118475, https://openalex.org/W2593111137, https://openalex.org/W1987204459, https://openalex.org/W2403400382, https://openalex.org/W2117115065, https://openalex.org/W2343682798, https://openalex.org/W2736581406, https://openalex.org/W2099900951, https://openalex.org/W2735904407, https://openalex.org/W2564334587, https://openalex.org/W2472071085, https://openalex.org/W1972184110, https://openalex.org/W2567803812, https://openalex.org/W2419439766, https://openalex.org/W2569464488, https://openalex.org/W2624660329, https://openalex.org/W2612327959, https://openalex.org/W2865352686, https://openalex.org/W2406250479, https://openalex.org/W2160927412, https://openalex.org/W2053606278, https://openalex.org/W2275678839, https://openalex.org/W2949273159, https://openalex.org/W2070050178, https://openalex.org/W2765496927, https://openalex.org/W2624985855, https://openalex.org/W2560367415, https://openalex.org/W2618667882, https://openalex.org/W2408932313 |
| referenced_works_count | 64 |
| abstract_inverted_index.a | 35, 185 |
| abstract_inverted_index.By | 112 |
| abstract_inverted_index.In | 91 |
| abstract_inverted_index.To | 22 |
| abstract_inverted_index.an | 5, 97 |
| abstract_inverted_index.as | 214 |
| abstract_inverted_index.in | 71, 102, 134 |
| abstract_inverted_index.is | 105, 128 |
| abstract_inverted_index.of | 4, 37, 44, 56, 179, 217 |
| abstract_inverted_index.on | 196 |
| abstract_inverted_index.to | 18, 33, 73, 177 |
| abstract_inverted_index.we | 95, 122 |
| abstract_inverted_index.TME | 114, 127, 208 |
| abstract_inverted_index.The | 0 |
| abstract_inverted_index.and | 13, 59, 85, 118, 154, 159, 204 |
| abstract_inverted_index.but | 137 |
| abstract_inverted_index.for | 107, 143, 188 |
| abstract_inverted_index.has | 30, 52 |
| abstract_inverted_index.may | 16, 205 |
| abstract_inverted_index.not | 63, 140, 162 |
| abstract_inverted_index.our | 42, 189 |
| abstract_inverted_index.the | 54, 66, 74, 92, 108, 125, 180, 197, 215 |
| abstract_inverted_index.two | 78, 212 |
| abstract_inverted_index.yet | 64 |
| abstract_inverted_index.LUAD | 158, 181 |
| abstract_inverted_index.LUSC | 160, 167 |
| abstract_inverted_index.been | 31 |
| abstract_inverted_index.cell | 26, 88, 115, 146 |
| abstract_inverted_index.does | 139 |
| abstract_inverted_index.end, | 24 |
| abstract_inverted_index.have | 62 |
| abstract_inverted_index.hold | 141 |
| abstract_inverted_index.lung | 27, 45, 82, 86, 109, 135, 144, 202 |
| abstract_inverted_index.shed | 194 |
| abstract_inverted_index.show | 123 |
| abstract_inverted_index.that | 104, 124 |
| abstract_inverted_index.this | 23, 138 |
| abstract_inverted_index.true | 142 |
| abstract_inverted_index.were | 161 |
| abstract_inverted_index.when | 175 |
| abstract_inverted_index.with | 130 |
| abstract_inverted_index.work | 51 |
| abstract_inverted_index.(TME) | 69 |
| abstract_inverted_index.NSCLC | 57, 80, 103, 218 |
| abstract_inverted_index.These | 192 |
| abstract_inverted_index.cells | 12, 15 |
| abstract_inverted_index.data, | 121 |
| abstract_inverted_index.light | 195 |
| abstract_inverted_index.major | 79 |
| abstract_inverted_index.shown | 32 |
| abstract_inverted_index.state | 101 |
| abstract_inverted_index.these | 211 |
| abstract_inverted_index.those | 178 |
| abstract_inverted_index.tumor | 1, 67, 99 |
| abstract_inverted_index.which | 10 |
| abstract_inverted_index.while | 49 |
| abstract_inverted_index.(LUAD) | 84 |
| abstract_inverted_index.cancer | 14, 28, 46, 203 |
| abstract_inverted_index.immune | 11, 171 |
| abstract_inverted_index.marker | 173 |
| abstract_inverted_index.recent | 50 |
| abstract_inverted_index.scores | 117 |
| abstract_inverted_index.study, | 94 |
| abstract_inverted_index.system | 8 |
| abstract_inverted_index.tumors | 156 |
| abstract_inverted_index.within | 157, 201 |
| abstract_inverted_index.(LUSC). | 90 |
| abstract_inverted_index.(NSCLC) | 29 |
| abstract_inverted_index.RNA-seq | 119 |
| abstract_inverted_index.between | 77, 152, 210 |
| abstract_inverted_index.effects | 200 |
| abstract_inverted_index.further | 207 |
| abstract_inverted_index.patient | 132 |
| abstract_inverted_index.present | 93 |
| abstract_inverted_index.regards | 72 |
| abstract_inverted_index.results | 193 |
| abstract_inverted_index.samples | 168 |
| abstract_inverted_index.studies | 61 |
| abstract_inverted_index.subtype | 163 |
| abstract_inverted_index.therapy | 219 |
| abstract_inverted_index.thereby | 40, 183 |
| abstract_inverted_index.through | 9 |
| abstract_inverted_index.variety | 36 |
| abstract_inverted_index.However, | 48 |
| abstract_inverted_index.Instead, | 165 |
| abstract_inverted_index.activate | 34 |
| abstract_inverted_index.compared | 176 |
| abstract_inverted_index.consists | 3 |
| abstract_inverted_index.elevated | 170 |
| abstract_inverted_index.enriched | 106 |
| abstract_inverted_index.examined | 65 |
| abstract_inverted_index.globally | 70 |
| abstract_inverted_index.identify | 96 |
| abstract_inverted_index.inflamed | 126 |
| abstract_inverted_index.offering | 184 |
| abstract_inverted_index.outcomes | 76 |
| abstract_inverted_index.pathways | 151 |
| abstract_inverted_index.putative | 186 |
| abstract_inverted_index.regulate | 19 |
| abstract_inverted_index.samples, | 182 |
| abstract_inverted_index.squamous | 87, 145 |
| abstract_inverted_index.subtype. | 111 |
| abstract_inverted_index.subtypes | 213 |
| abstract_inverted_index.survival | 75, 133 |
| abstract_inverted_index.Moreover, | 148 |
| abstract_inverted_index.carcinoma | 89 |
| abstract_inverted_index.encourage | 206 |
| abstract_inverted_index.favorable | 131 |
| abstract_inverted_index.landscape | 216 |
| abstract_inverted_index.non-small | 25 |
| abstract_inverted_index.organized | 7 |
| abstract_inverted_index.possessed | 169 |
| abstract_inverted_index.regulated | 150 |
| abstract_inverted_index.specific. | 164 |
| abstract_inverted_index.subtypes: | 81 |
| abstract_inverted_index.utilizing | 113 |
| abstract_inverted_index.anti-tumor | 20 |
| abstract_inverted_index.associated | 129 |
| abstract_inverted_index.broadening | 41 |
| abstract_inverted_index.carcinoma. | 147 |
| abstract_inverted_index.checkpoint | 172 |
| abstract_inverted_index.enrichment | 116 |
| abstract_inverted_index.expression | 120, 174 |
| abstract_inverted_index.immunology | 58 |
| abstract_inverted_index.importance | 55 |
| abstract_inverted_index.prognosis, | 60 |
| abstract_inverted_index.prognostic | 190, 199 |
| abstract_inverted_index.communicate | 17 |
| abstract_inverted_index.explanation | 187 |
| abstract_inverted_index.exploration | 209 |
| abstract_inverted_index.highlighted | 53 |
| abstract_inverted_index.immunogenic | 98 |
| abstract_inverted_index.intricately | 6 |
| abstract_inverted_index.mechanisms, | 39 |
| abstract_inverted_index.progresses. | 220 |
| abstract_inverted_index.immunological | 38, 198 |
| abstract_inverted_index.observations. | 191 |
| abstract_inverted_index.understanding | 43 |
| abstract_inverted_index.adenocarcinoma | 83, 110 |
| abstract_inverted_index.differentially | 149 |
| abstract_inverted_index.immunobiology. | 47 |
| abstract_inverted_index.adenocarcinoma, | 136 |
| abstract_inverted_index.immune-excluded | 155 |
| abstract_inverted_index.immune-inflamed | 153, 166 |
| abstract_inverted_index.immunogenicity. | 21 |
| abstract_inverted_index.microenvironment | 2, 68, 100 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 90 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/11 |
| sustainable_development_goals[0].score | 0.41999998688697815 |
| sustainable_development_goals[0].display_name | Sustainable cities and communities |
| sustainable_development_goals[1].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[1].score | 0.4000000059604645 |
| sustainable_development_goals[1].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.85291151 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |